Treatment before and after surgery for stomach cancer
Treatments studied
This study tests whether adding the immunotherapy drug durvalumab to standard chemotherapy before and after surgery can help people with stomach or gastroesophageal junction cancer. It aims to improve outcomes for patients whose cancer can be surgically removed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have stomach cancer or gastroesophageal junction cancer that can be removed with surgery.
- You have not had any previous treatment for this cancer, like chemotherapy or radiation.
- You are in good enough health to receive chemotherapy before surgery (ECOG score 0 or 1).
- You have adequate organ and bone marrow function, as shown by blood tests.
- You can provide a tumor tissue sample to check for PD-L1 status.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of chemotherapy and an immunotherapy drug (durvalumab) given before surgery for stomach or gastroesophageal junction cancer. The goal is to see if it shrinks the tumor and improves outcomes.
This trial tests a combination of chemotherapy (FLOT), an immunotherapy drug (pembrolizumab), and short-course radiation before surgery for gastroesophageal junction cancer. The goal is to see if this approach improves outcomes.
This trial tests combining chemotherapy with an immunotherapy drug called durvalumab before and after surgery for stomach or lower esophagus cancer. The goal is to see if this approach helps prevent the cancer from coming back.
This trial tests adding an immunotherapy drug (tislelizumab) to standard chemotherapy (FLOT) before surgery for people with stomach or esophagus cancer that can be removed but hasn't spread. The goal is to see if this combination is safe and works better than chemotherapy alone.
This trial tests a combination of two treatments: an immunotherapy drug (pembrolizumab, which helps your immune system fight cancer) and chemotherapy (FLOT) for advanced stomach or esophageal junction cancer. The goal is to see if this combination is safe and works better than standard care.
This trial tests giving a combination of immunotherapy, a growth factor to boost white blood cells, and chemotherapy before surgery for stomach cancer. The goal is to shrink the tumor and improve surgical outcomes.
Hear when a new Gastric trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.